Basic Mechanisms

Hypoxemic respiratory failure refers to the inability of the respiratory system to maintain satisfactory levels of oxygen in the arterial blood.³ The five basic mechanisms of hypoxemia are listed in Box 37.2. Ventilation-perfusion abnormality is the most common.^2,3 Multiple mechanisms may be instrumental in the development of respiratory failure. Most of the abnormalities will improve with the administration of supplemental oxygen, except for a shunt abnormality in which the PaO₂ continues to be low despite the administration of high levels of supplemental oxygen. The shunt may be either intracardiac (such as a right-to-left shunt through a patent foramen ovale) or intrapulmonary (as seen with pneumonia or ARDS).^5,6 A diffusion abnormality is infrequently the cause of hypoxemia in clinical practice and typically is only significant in the setting of tachycardia, high cardiac outputs, and when the diffusion capacity is below 25% of predicted.³

Assessment of Oxygenation

The hallmark of type 1 respiratory failure is hypoxemia, which is primarily assessed by the PaO₂ of an arterial blood gas (ABG). An estimate of the patient’s oxygenation status can be obtained by measuring the oxygen saturation using a pulse oximeter. An appreciation of the sigmoid shape of the oxyhemoglobin dissociation curve allows for a rough estimation of the PaO₂ (Fig. 37.2). The curve will shift rightward or leftward in relation to changes in the pH, PaCO₂, temperature, and PO₄⁻² concentration.⁷ Determination of the ABG and knowledge of the exact FIO₂ allows for the calculation of the alveolar-arterial oxygen gradient³ (A-a gradient) using the formula PAO₂ − PaO₂ = A-a gradient; thus,

where

The A-a gradient is FIO₂ dependent and will increase as the FIO₂ increases. Because of this FIO₂ dependency, some have preferred to evaluate oxygenation abnormalities by calculating the PaO₂/PAO₂ ratio, which is independent of the FIO₂.³ For simplicity’s sake, many individuals use the PaO₂/FIO₂ ratio as a measure of oxygenation abnormality. This value is used in the definition of ARDS and has gained wide-scale acceptance as a measure of abnormal oxygenation.⁸ The shunt fraction or venous admixture can also be calculated while a patient breathes 100% oxygen and has reached steady-state oxygenation.

Assessment of Ventilation

The hallmark feature of inadequate ventilation is the presence of an elevated PaCO₂ with or without the presence of hypoxemia.3,9 In the adult population the best method to detect an elevated PaCO₂ is with an ABG measurement. Noninvasive evaluation of ventilation in the critically ill adult, using end-tidal CO₂ (PetCO₂) measurements or transcutaneous CO₂ (PtcCO₂) determinations, is not as reliable as it is in the healthy adult or the neonate, respectively.⁷

Clinical Manifestations

The risk factors for developing acute respiratory failure include the postoperative state, preexisting chronic illness, malnutrition, advanced age, morbid obesity, chronic bronchitis, and cigarette smoking. The clinical manifestations of respiratory distress may be subtle and nonspecific or may be obvious to even the untrained observer. The patient with respiratory distress may have an abnormal respiratory rate (too high or low) or display an irregular pattern of breathing. The patient with respiratory distress may evidence gasping ventilation, nasal flaring, or use of the accessory muscles of respiration. Intercostal retractions may be seen, and the patient may exhibit paradoxical respiratory movement. Typically, patients with acute respiratory failure, whether type 1 or type 2, will have altered heart rate and blood pressure. The majority will evidence a sympathetic response with tachycardia and hypertension, but patients may be hypotensive and bradycardic. Cardiac arrhythmias may be seen in both type 1 and type 2 respiratory failure. Patients with acute respiratory failure will usually be in distress and often appear apprehensive.2,9 Many will be diaphoretic and have altered mental status or level of consciousness. Hypercapnic patients may demonstrate signs of a respiratory encephalopathy including somnolence, coma, asterixis, seizures, tremors, or myoclonic jerks. Papilledema and congested conjunctivae may be present. Type 1 respiratory failure patients may appear cyanotic.⁹

1. Timing—patients with ARDS should be identified within 72 hours of a recognized risk factor and nearly all patients should be identified within 7 days.

2. Chest imaging—bilateral opacities consistent with pulmonary edema are seen on chest radiograph or chest computed tomography (CT) scan.

3. Origin of pulmonary edema—ARDS may be present in the setting of coexisting cardiogenic edema or volume overload if in the opinion of the treating physicians the respiratory failure is not fully explained by these conditions and there is a recognized risk factor for ARDS. In the absence of a recognized risk factor for ARDS there should be some objective assessment of cardiac function such as echocardiography or pulmonary capillary wedge pressure measurement.

4. Oxygenation—because PEEP can affect the PaO₂/FIO₂ ratio there should be a minimum of 5 cm H₂O PEEP and 10 cm H₂O in those patients with severe ARDS (PaO₂/FIO₂ < 100).³⁰

Risk Factors

It has been recognized that ARDS may arise in association with a number of clinical conditions or risk factors, with sepsis being the most common (Box 37.4).^{8,18,21,27,33–37} Various studies report that approximately 5% to 40% of septic patients will develop ARDS.^8,18,36 Shock (prolonged hypotension) and the systemic inflammatory response syndrome (SIRS) are also common risk factors. Other frequently encountered clinical risk factors include multiple emergency transfusions; aspiration injury; near-drowning; pancreatitis; trauma (particularly lung contusion, fat emboli from long bone fractures); burns; cardiopulmonary bypass; and disseminated intravascular coagulation (DIC). These clinical risk factors are synergistic, and when more than one of the clinical risk factors is present, the likelihood of ARDS is greater than just the sum of the collective risk factors.^8,17 The clinical risk factors associated with the development of ARDS appear to greatly influence the expected outcome. Whether ALI and ARDS arise from a direct pulmonary insult or from an extrapulmonary cause impacts the subsequent response to PEEP and ventilatory support (Box 37.5).¹⁹ Age also has an impact on the likelihood for ARDS development.³⁸ Older individuals have a greater likelihood of developing ARDS from most of the risk factors noted earlier. In the setting of trauma the risk for ARDS seems to peak in the sixth and seventh decades and then declines.³⁸

Negative pressure (postobstructive) pulmonary edema (NPPE or POPE) is a type of noncardiogenic pulmonary edema that can manifest as ARDS.³⁹ It is rare (five cases reported from a large tertiary medical ICU in 4 years),⁴⁰ can range in severity from mild hypoxemia treated with low-flow supplemental oxygen to profound hypoxemia requiring mechanical ventilation, and may even present as alveolar hemorrhage.^41–45 It is believed to be caused by increased vascular permeability resulting in alveolar and capillary damage from large levels of negative intrathoracic pressure generated by attempting to inspire against an occluded airway or airway obstruction.^46,47 This leads to a protein-rich alveolar exudate impairing gas exchange in mild-to-moderate cases and leaking of capillary blood into the alveoli in more severe circumstances. Most of the reported cases are related to surgical procedures: thyroidectomy,^48,49 septorhinoplasty,⁵⁰ tonsillectomy/adenoidectomy,⁵¹ mandibular open reduction and internal fixation,⁵² or cryosurgery for a tracheal obstruction.⁵³ Nonoperative conditions leading to NPPE have included laryngospasm,^54,55 occlusion of an endotracheal tube,^56,57 excessive tube thoracostomy suction pressure,⁵⁸ nonlethal hanging,⁵⁹ and even hiccups.^60,61 The common element is the rapid relief of a large airway occlusion. Patients often have no underlying cardiopulmonary disorders. NPPE may account for a small percentage of immediate postoperative extubation failures, particularly if an unrecognized mainstem intubation is present in an awake and spontaneously breathing patient. Clinical manifestations of hypoxemia and respiratory distress may be delayed up to 6 hours.⁴⁷ Therapy is supportive with supplemental oxygen and, if needed, positive-pressure ventilation (invasive or noninvasive).

Elevated intracranial pressures, either from traumatic brain injury or intracerebral hemorrhage, or status epilepticus can induce an ARDS-like clinical syndrome termed neurogenic pulmonary edema (NPE).62,63 Although the exact mechanisms are not clear, an abrupt and massive release of catecholamines from injured neuronal tissues is thought to act directly on the lung parenchymal vasculature to promote a “capillary leak” of a protein-rich exudate as well as an increase in pulmonary vascular resistance⁶⁴ in addition to inducing a neurohumoral (takotsubo) cardiomyopathy.^65–67 The cardiomyopathy has the distinctive echocardiographic feature of ventricular apical ballooning and can persist for months.⁶⁸

Incidence and Prevalence

The exact incidence and prevalence of ARDS has been variable and related to definitions used (Box 37.6).^8,38 Early reports suggested that there were 150,000 patients with ARDS each year in the United States.^8,33,36,69 This statistic led to an estimated incidence of 75 cases per 100,000 population. Proposed estimates have suggested that the incidence of ARDS ranges from 1.5 to 64 cases per 100,000 population.^38,69,70 A recent study evaluated the incidence and outcome of ALI in mechanically ventilated patients aged 15 or older cared for at 21 hospitals in and around King County, Washington, over a 15-month observation period.³⁸ The crude incidence of ALI was 78.9 per 100,000 person-years, and the incidence of ARDS was 58.7 per 100,000 person-years. On the basis of their results, the authors estimated the annual number of U.S. episodes was 332,100 cases of ARDS. The authors noted that increasing age was associated with an increased incidence and mortality rate in ARDS. A recent prospective observational study using the AECC definition and lung protective ventilatory support strategies in Spain (the ALIEN study) reported an incidence of 7.2 per 100,000 population per year for ARDS with an ICU and hospital mortality rate of 42.7% and 47.8%, respectively.⁷¹

Clinical Manifestations

When ARDS becomes clinically apparent, the patient is usually noted to be in significant distress manifesting dyspnea, tachypnea, visible signs of respiratory distress, and increased work of breathing.8,23,33,36 The typical presentation is manifest as an acute catastrophic complication in a patient who has one or more of the clinical risk factors for the development of this form of ARDS. The precipitating injury need not directly involve the pulmonary system.^8,36,72 Past definitions have emphasized the need to exclude patients with previous or known chronic pulmonary or cardiovascular diseases.^19–21,27 The AECC definition excluded patients with elevated left-sided heart filling pressures and chronic infiltrative lung disease as the cause of the radiographic or physiologic alterations, but the new Berlin definition will allow for the concomitant presence of ARDS and cardiac edema/volume overload as long as the predominant process is thought to be ARDS.^21,30

The hallmark of ARDS is the presence of hypoxemia despite the administration of high concentrations of inspired oxygen, evidence of an increase in the shunt fraction, a decrease in pulmonary compliance, and an increase in the dead space ventilation.8,24,30 The chest radiographic manifestation of ARDS is the presence of diffuse, bilateral pulmonary infiltrates with a normal cardiac silhouette. Recent reports have cautioned that even among trained experts there is often disagreement concerning the interpretation of the chest radiograph.^31,29,69,73 Chest CT has also demonstrated that the radiographic injury is not homogeneous and has a predominance in the dependent portions of the lung.^8,43 It is important to remember that ARDS is a clinical syndrome and the diagnosis is made clinically, not on the basis of a single radiograph, ABG analysis, or laboratory test.

Pathologic Manifestations

Typically, type 1 alveolar cells compose the major gas exchange surface of the alveolus and are integral to the maintenance of the permeability barrier function of the alveolar membrane.⁸ Type 2 pneumocytes are the progenitors of type 1 cells and are responsible for surfactant production and homeostasis.⁸ During ARDS there is damage to the capillary endothelial and the alveolar epithelial cells.⁸ Cellular injury and alteration of the normal barrier function results in a permeability defect that gives way to flooding of the alveoli with protein-rich fluid and inflammatory cells.^8,33,74 This results in the alteration of pulmonary mechanics, physiology, and gas exchange.^8,74 There is alteration of surfactant that results from damage to the type 2 pneumocyte and from the inactivation and dilution of alveolar surfactant from the protein and fluid that have entered into the alveolar space, respectively.^75,76 Surfactant dysfunction can lead to atelectasis and a further reduction in pulmonary compliance.^8,75–78 In addition, dysfunction of the alveolar epithelial cells can impair the resorption of fluid from the alveolar space, which augments the parenchymal injury process and gas exchange abnormalities.^8,79

The observed pathologic findings in ARDS depend on the timing of the tissue sampling. During the initial stages of clinically evident lung injury there is histologic evidence of diffuse alveolar damage.⁸ Histologic features of the injury include microthrombi composed of platelets and white blood cells within the capillary lumen, denudation of the alveolar epithelial lining cells, swelling of the capillary endothelial cells, interstitial and alveolar infiltration by polymorphonuclear leukocytes (PMNLs), and hyaline membrane formation within the alveoli.⁸ Grossly, the lungs appear heavy and wet. Later, areas of type 3 collagen deposition with fibrosis will be present.⁷⁹ An intense inflammatory reaction involving PMNLs, activated monocytes, macrophages, and endothelial cells is present in the fibroproliferative phase of lung injury.^76,80,81 Pro- and anti-inflammatory molecules produced by these activated cells may be found in the circulating blood and bronchoalveolar lavage (BAL) fluid.^81–83 This phase may be followed by fibrosis, but this fibrosis does not appear to have the same permanence as typical fibrosis would have and may actually resolve over time in survivors of the injury.⁸⁴

Pathophysiology

ARDS may develop as a result of epithelial or endothelial cell injury.8,13,85,86 Both sites of injury and cells are important for maintenance of normal barrier function and are capable of initiating an inflammatory response. In the majority of clinical settings the initial site of the ARDS involves the capillary endothelial cell, which may be the initial manifestation of a “panendothelial cell injury” resulting from SIRS.⁸³ Endothelial cell injury compromises the integrity of the vascular barrier and results in transudation of fluid and inflammatory mediators into the interstitial tissues and ultimately into the alveoli.^8,13 The frequent occurrence and early involvement of lung dysfunction as a component of multiple organ dysfunction/failure lends support to the hypothesis of a panendothelial cell injury as one of the target injuries in the setting of SIRS.⁸⁷

The complex pathophysiologic processes that culminate in the production of ARDS involve a delicate balance between the body’s proinflammatory and anti-inflammatory responses to the inciting clinical event.83,87 The balance that exists between the various inflammatory molecules or mediators and the endogenous compensatory responses evoked by the inflammatory response will dictate whether or not lung injury and other forms of organ dysfunction will develop.⁸¹ The ensuing interaction between SIRS and the compensatory anti-inflammatory response syndrome (CARS) will thus determine whether a patient successfully deals with an injury or is predisposed to develop organ dysfunction (excessive SIRS response) or immunosuppression and infectious complications (excessive CARS response).^83,87 This mixed antagonistic response syndrome (MARS) has tremendous impact on the fate of the critically ill patient.⁸⁷

Management Strategies

Basic management strategies for patients with ARDS are listed in Box 37.7.^{8,18,21,23,33,36,88} Initial attention must be directed to providing lung protective ventilator support and identification of the predisposing underlying clinical risk factor(s) or condition(s), and there should be specific treatment directed at the underlying or predisposing disorder.^8,21–23 The recognition of sepsis and infection as frequent causes of ARDS should prompt an aggressive search for undiagnosed foci of infection and the administration of appropriate antimicrobial treatment and use of surgical drainage procedures as indicated.^15,17,89

The cornerstone of supportive management is the provision of mechanical ventilatory support.8,21–23 Recent experimental and clinical data report significant survival benefit from the use of lung protective ventilatory support strategies.^90,91 The primary goal of this support is to improve oxygenation and ensure that the lung is allowed to heal and avoid further injury. Use of nonprotective ventilatory support strategies may have a role in the persistent proinflammatory response and the development of multiple organ dysfunction syndrome (MODS) and multiple organ failure (MOF).^90–93